Background
Gastric cancer, cancer, unresectable or recurrent gastric cancer, tumour, adenocarcinoma
GASTRIC CANCER, CANCER, TUMOUR, ADENOCARCINOMA
Gastric cancer (GC) is the fifth most common and fourth most deadly cancer worldwide [As later-line treatment in patients with advanced gastric and EGJ adenocarcinoma, monotherapy with trifluridine/tipiracil (FTD/TPI), irinotecan, and nivolumab are recommended in the Japanese treatment guideline, regardless of HER2 status [FTD/TPI is an oral cytotoxic chemotherapeutic agent comprising trifluridine, an antineoplastic thymidine analog, and tipiracil, which prevents trifluridine degradation. The TAGS, an international joint phase III study to examine the prolongation of overall survival (OS) of FTD/TPI over placebo in patients with unresectable or recurrent gastric cancer refractory to standard treatment, showed that FTD/TPI monotherapy was significantly superior to the placebo (hazard ratio [HR]: 0.69, 95% confidential interval [CI]: 0.56–0.85, one-sided Recently, combination therapy with FTD/TPI and angiogenesis inhibitors for pre-treated patients with gastric or EGJ adenocarcinoma has been implemented globally. In Japan, a single-arm phase II study of FTD/TPI plus ramucirumab (RAM) showed promising outcomes in terms of tumour response, PFS, associated with the feasible safety profile [